BAY Stock Overview
Operates as a life science company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €88.00 |
| 52 Week High | €155.00 |
| 52 Week Low | €86.07 |
| Beta | 1 |
| 11 Month Change | -20.86% |
| 3 Month Change | -26.47% |
| 1 Year Change | -39.25% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAY | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -0.5% | 3.9% | -0.2% |
| 1Y | -39.3% | 49.6% | 0.3% |
Return vs Industry: BAY underperformed the Polish Pharmaceuticals industry which returned 49.6% over the past year.
Return vs Market: BAY underperformed the Polish Market which returned 0.3% over the past year.
Price Volatility
| BAY volatility | |
|---|---|
| BAY Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.4% |
| 10% least volatile stocks in PL Market | 2.9% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine BAY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 94,245 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAY fundamental statistics | |
|---|---|
| Market cap | zł84.34b |
| Earnings (TTM) | -zł3.81b |
| Revenue (TTM) | zł202.62b |
0.4x
P/S Ratio-22.1x
P/E RatioIs BAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAY income statement (TTM) | |
|---|---|
| Revenue | €46.74b |
| Cost of Revenue | €20.03b |
| Gross Profit | €26.71b |
| Other Expenses | €27.59b |
| Earnings | -€880.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 57.15% |
| Net Profit Margin | -1.88% |
| Debt/Equity Ratio | 134.1% |
How did BAY perform over the long term?
See historical performance and comparison